Justin C. Boysen

Mayo Clinic — United States

Immunology and Microbiology · Life Sciences

16h-index1.3kcitations96works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(58), Chronic Lymphocytic Leukemia Research(51), CAR-T cell therapy research(38), Lymphoma Diagnosis and Treatment(14), Extracellular vesicles in disease(7)

Publications96 total

Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Spatial multiomics reveal a critical role for TIM4-expressing macrophages in blast transformation of chronic myelomonocytic leukemia
Blood·2025Open Access
Progressive T cell defects correlate with disease outcome in high-count monoclonal B-cell lymphocytosis
Leukemia·2025
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figure Legends from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S1 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Table S2 from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Supplementary Figures from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Data from AXL inhibition improves the anti-tumor activity of chimeric antigen receptor T cells
2024Open Access
Aberrant activation of AXL may drive progression of squamous cell carcinoma in CLL patients: a mechanistic study with clinical implications
British Journal of Cancer·2024Open Access
Cellular Interactions within Clonal Dendritic Cell Aggregates Drive Immune Tolerance in Chronic Myelomonocytic Leukemia Bone Marrow Microenvironment
Blood·2023· 1 cited
PD-1 Expression in Lymphoma Cells Mediates Cellular Proliferation By Engaging Phosphatase SHP-1/SHP-2
Blood·2023Open Access
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2023Open Access
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Neil E. Kay(46), Sutapa Sinha(27), Sameer A. Parikh(26), Steven L. Warner(22), Saad S. Kenderian(22), Wei Ding(20), Michelle J. Cox(19), Reona Sakemura(19), Mehrdad Hefazi(19), Tait D. Shanafelt(18), Kendall J. Schick(18), Renee C. Tschumper(17), Timothy G. Call(17), Asish K. Ghosh(16), Charla Secreto(16), Michael J. Hansen(16), Michael W. Ruff(15), Claudia Manriquez Roman(14), Erin E. Tapper(14), Cynthia L. Forsman(14)